research reports and media, page-737

Hi Mangoman,

I found this informative piece about the GID Bio trials after digging around a bit:

https://journals.sagepub.com/stoken/default+domain/KQTSBVJKGFSNWJ9FHC4A/full

whilst informative, I couldn't tell too much about whether or not they were younger people who were used in the trial. It mentions the recruitment was for 40-75 year olds, but they also excluded co-morbidities, which generally exist more commonly in older people; but couldn't gauge that from the journal. it also excluded those with Lesions >1cm, whereas I believe iPPS is meant for OA with BMEL.

The other thing was the GID Bio treatment showed no impact on the thickness of the cartilage, whereas iPPS was indicated in our phase 2b trial to be disease modifying. But having said that, were the disease modifying capabiities of iPPS going to be an endpoint of our trial?